[Perspectives] Treatment toxicity in endometrial cancer: can we identify and manage it better?

We thank Dr Melanie Powell and Dr Remi Nout for taking the time to share their expertise on high-risk endometrial cancer during the March 17–18 #radonc journal club on Twitter. During our conversation, we discussed the results of the PORTEC-3 trial, which confirms the findings of other randomised trials: a reduced risk of relapse by adding chemotherapy to radiotherapy, without improving overall survival. The risk of distant relapse was not significantly lower with chemotherapy, suggesting that a clear survival benefit might not be observed with a longer follow-up.

https://ift.tt/2FhHhZr